熱門資訊> 正文
小RFK结束COVID-19药物的紧急使用授权
2026-07-01 02:30
- HHS Secretary Robert F. Kennedy Jr. has terminated Emergency Use Authorizations for drugs and medical devices to treat COVID-19.
- The EUAs for drugs and biologics will end in 12 months and in 180 days for medical devices.
- COVID vaccines are not impacted by today's action given that the three shots available in the US, manufactured by Moderna (MRNA), Pfizer (PFE)/BioNTech (BNTX), and Novavax (NVAX) have received traditional approval following their own EUAs.
- Drugs such as Pfizer's Paxlovid (nirmatrelvir/ritonavir) and Merck's (MRK) Lagrevio (molnupiravir) are impacted by the directive.
More on Pfizer, Merck
- Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff
- Antibody-Drug Conjugates: Not Quite Worked Out Yet
- Merck's Oncology Engine Is Still Accelerating
- FDA commissioner contenders down to three - report
- Record-setting healthcare M&A activity to extend through H2: PwC
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。